Thursday, November 9, 2023


AKWEL (FR0000053027, AKW, PEA-eligible), parts and systems manufacturer for the automotive and heavy-vehicle industry, specialist in fluid management, mechanisms and structural parts for electric vehicles, has recorded, over the first 9 months of 2023, a consolidated turnover of €781.9M.

Consolidated turnover

in €m — unaudited 2023 2022 Variation Like-for-like variation (1)
1st quarter 273.7 245.8 +11.3% +14.6%
2nd quarter 259.6 242.3 +7.1% +13.0%
3rd quarter 248.7 251.1 -0.9% +9.2%
Nine-month total 781.9 739.2 +5.8% +12.3%

(1)   At constant scope and exchange rates.

NB: The IAS 29 standard “Financial Reporting in Hyperinflationary Economies” now applies, resulting in the reprocessing of the first and second quarters, which had already been recorded and processed when the half-yearly results were published.

AKWEL has completed its third quarter of 2023 with a consolidated turnover of €248.7M, a slight decline of -0.9% in comparison to 2022. The Group’s performance is staying dynamic with an increase of +9.2% at constant scope and exchange rates.

Over 9 months, AKWEL’s turnover, at constant scope and exchange rates, is up +12.3% propelled by activity in France and Europe.

The most dynamic product lines were Air (+23.6%), Washing (+19.5%) and Cooling (+9.7%) activities, while the Structural Parts for electric vehicle is continuing to grow with a turnover of €15.3M (+71.7%).

The consolidated net cash without lease obligations reached €108.1M on September 30, 2023, with an amount of €42.6M investments over the first 9 months.

In terms of continuing the performance over the first 9 months, AKWEL confirms that it is expecting an annual revenue growth +10%, at constant scope and exchange rates. This growth will result an increase of at least +5% in recorded data.

An independent family business, trading on Euronext Paris, AKWEL is a parts and systems manufacturer for the automotive and heavy-vehicle industry, and a specialist in fluid management, mechanisms and structural parts for electric vehicles. The Group achieves this with their first-rate industrial and technological know-how in mastering the application and processing of materials (plastic, rubber, metal) and mechatronic integration.

Working in 21 countries across 5 continents, AKWEL employs 9500 employees worldwide.



GlobeNewswire Distribution ID 1000898600

Nigerian Lawyer Zannah Bukar Mustapha Receives Prestigious Global Citizen Award

Nigerian Lawyer Zannah Bukar Mustapha Receives Prestigious Global Citizen Award

Internationally recognized humanitarian, philanthropist, and Founder of the Future Prowess Foundation School in Nigeria, Zannah Bukar Mustapha, has been named as the 2023 recipient of the Global Citizen Award at the 17th Global Citizenship Conference in Dubai, UAE.

LONDON, Nov. 09, 2023 (GLOBE NEWSWIRE) — Internationally recognized humanitarian, philanthropist, and Founder of the Future Prowess Foundation School for orphans and less privileged children Zannah Bukar Mustapha has been named as the 2023 recipient of the Global Citizen Award, an annual tribute presented by leading international residence and citizenship advisory firm Henley & Partners, in partnership with the Swiss non-profit humanitarian organization Andan Foundation.

The prestigious award, which honors an individual who shows exceptional courage and commitment towards improving and supporting the global community, was presented at a gala reception during the 17th annual Global Citizenship Conference at the Shangri-La Hotel DIFC in Dubai, UAE, attended by heads of government, policymakers, leading academics, private client advisors, family offices, as well as many wealthy entrepreneurs and investors.


Mr. Mustapha played a critical role in mediating the release of over 100 of the Chibok school girls who were kidnapped by Islamic insurgency group Boko Haram in a remote part of Nigeria in April 2014, giving rise to the international #BringBackOurGirls campaign. The school he founded in 2007 in Maiduguri — the capital of Borno State and the epicenter of the Boko Haram rebellion — provides free education, meals, uniforms, and healthcare to children on both sides of the conflict as a sign of the reconciliation he hopes to achieve in the region.

Chairman of Henley & Partners and Founder of the Andan Foundation Dr. Christian H. Kaelin says Mr. Mustapha is a most worthy and inspiring recipient of the award. “As a champion for the safety and education rights of all displaced and orphaned children afflicted by the brutal violence in Northern Nigeria, Mr. Mustapha has demonstrated vision, exceptional courage, and innovation in driving change, and his actions and outlook are a valuable contribution towards a more just, peaceful, and tolerant world. He is a true ‘game changer,’ bridging gender, political, and religious divides by helping children on both sides of the conflict come together and learn under the same roof. We need more Zannah Mustaphas in the world.”

The Global Citizen Award selection process is based on a majority decision of the Global Citizen Award Committee. The award itself consists of a bespoke sculptural medal designed by leading Italian artist Antonio Nocera, an award certificate signed by the Chairman of the Global Citizen Award Committee, and a monetary prize of USD 25,000, which goes towards supporting the awardee’s humanitarian efforts. In addition, Henley & Partners commits to working closely with the awardee for a period of one year, raising awareness of their work and supporting the selected project through the firm’s network of more than 40 offices worldwide.

Since its inception, the Global Citizen Award has honored many remarkable individuals. The first laureate was German entrepreneur Harald Höppner, who set up the refugee humanitarian aid project Sea-Watch. Other previous recipients are Dr. Imtiaz Sooliman, Founder of the Gift of the Givers Foundation, Africa’s largest disaster relief organization, and Monique Morrow, Co-Founder of The Humanized Internet, a digital identity project that aims to bring hope to the estimated 1.1 billion individuals in the world who cannot prove their legal identity. Diep Vuong, Co-Founder and President of the Pacific Links Foundation, was awarded for her work in Southeast Asia, campaigning for the rights of those enslaved by human trafficking, and Prof. Dr. Padraig O’Malley received his Global Citizen Award in recognition of his work on conflict resolution and reconciliation in Iraq, Northern Ireland, and South Africa.

Thanking Henley & Partners and the Andan Foundation for their recognition of his work, Mr. Mustapha said, “Humanity’s interconnectedness in the global data sphere is now undeniable, constituting an expansive realm with limitless possibilities. In contrast, the unity among races, ethnicities, and citizens has grown increasingly delicate. Only global citizenship can heal.”

Media Contact:

Sarah Nicklin

Group Head of Public Relations


Mobile: +27 72 464 8965

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/73067ec7-8285-4333-849a-48dc9724ce41

GlobeNewswire Distribution ID 1000898595

Smart City Expo 2023 opens a New Urban Era with record-breaking figures

Smart City Expo closes a record-braking 2023 edition

Attendees gather at the access of Smart City Expo World Congress held at Fira de Barcelona’s Gran Via venue.

BARCELONA, Spain, Nov. 09, 2023 (GLOBE NEWSWIRE) — The 2023 edition of Smart City Expo World Congress (SCEWC), the leading international summit on cities and smart urban solutions organized by Fira de Barcelona, contributed to open a new era of urban innovation after registering record-breaking figures and holding the event together with Tomorrow.Mobility World Congress – organized with the EIT urban Mobility –, Tomorrow.Building and Tomorrow.Blue Economy. After three days, the events gathered over 25.300 attendees from 140 countries at Fira de Barcelona’s Gran Via venue.

The 600 experts discussed the different strategies being deployed worldwide to tackle the challenges that cities are facing in areas such as Mobility, Governance, Sustainability and Inclusion. Among the keynote speakers featured Nathan Blecharczyk, Co-Founder and Chief Strategy Officer of Airbnb; the President of FC Barcelona, Joan Laporta; computer scientist and expert in Algorithmic bias Margaret Mitchell; AI-specialized lawyer Micaela Mantegna; and former UK Minister for Energy & Clean Growth and sustainable development expert, Claire O’Neill.


Together, the events hosted a total of 1,106 exhibitors, 29.7% more than in 2022, who showcased their latest projects and solutions. Among these were industry leaders Aramco, Axis, BSM, Cisco, CBRE, Dassault Systemes, Dell, Deloitte, Drees&Sommer, FCC, Honeywell, Johnson Controls, KIA, Microsoft, Moventis, Nvidia, PTV Group, PWC, Racc, Renfe, Roshn Group, Samoo Architects & Engineers, Samsung C&T Corporation, Sener, Siemens, SPIE, Smart Ports: Piers of the Future, and Veolia.

Amongst the over 800 cities and countries present featured Brazil, China, Estonia, France, Germany, India, Italy, Japan, Korea, Mexico, Nordics, Poland, Portugal, Saudi Arabia, and USA, who showcased their latest initiatives including projects using Digital Twins to represent and monitor different urban areas or Artificial Intelligence to manage mobility and other city services.

The Director of Smart City Expo World Congress, Ugo Valenti, said: “The outcome of Smart City Expo 2023 has certified that we’re opening the door to a new era for cities, as our theme for this year stated, one of innovation and sustainability. For three days, we’ve seen how cities and companies have started to pave the way to a better future and we’re proud that our event and Barcelona have been chosen as the global hub for this joint effort.”

Smart City Expo World Congress will return the Gran Via venue in Barcelona for its thirteenth edition on 5-7 November, 2024.

For media requests please contact:

Salvador Bilurbina
email: sbilurbina@firabarcelona.com
phone: +34628162674

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/fc40c65b-954e-4b11-a81f-6c60d44f8ab8

GlobeNewswire Distribution ID 1000898603

OPEN Health Presenting Innovative Research on Capitalizing Data for Patient Access at ISPOR Europe

London, Nov. 09, 2023 (GLOBE NEWSWIRE) —
London, UK – November 9, 2023 – OPEN Health, a preeminent global provider of consultingHEOR and market accesspatient engagement, and scientific and creative communications services, will be presenting innovative research at the upcoming ISPOR Europe conference in Copenhagen, Denmark. OPEN Health experts will contribute to the event through workshops, panel discussions, and 24 posters. Key themes of OPEN Health’s research presented this year are patient preference, advanced modeling methodologies, and HTA policy changes. The majority of OPEN Health’s Scientific Office will be onsite to discuss the role of HEOR science in shaping policy, including Dr. Elisabeth Fenwick, Chief Scientific Officer; Professor Ben van Hout, Scientific Founder; Dr. Marco Boeri, Director of Preference Research and scientific lead for Patient-Centered Outcomes; Emanuele Arcà, MSc, Senior Research Consultant in Strategic Market Access; and Maarten Treur, MSc, Vice President and Global Head of Modeling & Meta-Analysis.

Dr. Elisabeth Fenwick, Chief Scientific Officer at OPEN Health, said: “I am extremely proud to see the research we do at OPEN Health being presented by our scientific experts at the ISPOR EU conference in Copenhagen. The range of research topics covered this year shows the extent of our expertise in advanced techniques as well as key therapeutic areas.”

Dr. Marco Boeri, Director of Preference Research and scientific lead for Patient-Centered Outcomes at OPEN Health, said: “The importance of patient preference information is that it brings a systematic approach to implement the idea of patient-focused drug development promoted by the FDA, the EMA, and various HTA bodies around the world. Indeed, the patient voice is key to patient adherence, and by helping to understand unmet needs, it is key to the success of a pharmaceutical product.”

Emanuele Arcà, MSc, Senior Research Consultant in Strategic Market Access, said: “We are in a dynamic period of policy changes for access and HTA across regional, national, and international settings. HTA is taking a more prominent role in ensuring sustainable access to health innovations, while health innovations become exponentially more complex and expensive. We at OPEN Health are committed to understanding and shaping such changes through research and stakeholder engagement.”

OPEN Health will be presenting a virtual panel on November 10, ahead of ISPOR, on: EU HTA Joint Clinical Assessments: Navigating Potential Challenges Ahead of 2025.” The panel is set to discuss several policy aspects regarding the current challenges and implications of the EU HTA regulation, covering topics such as the current position of EU HTA implementation, the major challenges expected across the industry, the stance of member states and various stakeholders, and strategies for the industry to prepare for joint clinical assessments. Register now to save your seat.

To learn more about our presence at ISPOR Europe, visit our website or meet the OPEN Health team at booth #C2-012 in Copenhagen.


About OPEN Health

OPEN Health unites deep scientific knowledge with wide-ranging specialist expertise to unlock possibilities that improve health outcomes and patient well-being. Working in partnership with our clients, we embrace our different perspectives and strengths to deliver fresh thinking and solutions that make a difference. OPEN Health is a flexible global organization that solves complex healthcare challenges across consulting, HEOR and market access, scientific communications, patient engagement, and creative omnichannel communications. For more information on OPEN Health, visit www.openhealthgroup.com.


Press contact:

OPEN Health

Candice Subero, Vice President, Global Marketing



Candice Subero
OPEN Health

GlobeNewswire Distribution ID 8976596

Meet the 50 most investible Canadian cleantech ventures transforming the future of climate solutions globally

CALGARY, Alberta, Nov. 09, 2023 (GLOBE NEWSWIRE) — Canada’s 50 most investible cleantech ventures have been announced by Foresight Canada, the country’s largest cleantech ecosystem accelerator. The Foresight 50 features inspiring cleantech ventures across a range of industries and sectors that provide solutions to some of society’s most pressing issues including green housing, emissions reduction, and food security.

According to the Climate Change Performance Index, Canada is currently in last place among G7 nations in its climate change performance and commitment – highlighting the urgent need to accelerate our pace to position Canada as a force of nature on the path to net zero. Cleantech is the key to fighting climate change.

Through this program, Foresight helps facilitate critical investment needs in Canadian cleantech. According to EDC’s latest annual cleantech report, Canada saw a record $1.2B invested in cleantech last year, the highest investment since 2018. The report also states that early stage funding is critical to the success of the country’s cleantech sector.

Foresight catalyzes made-in-Canada solutions by directly connecting innovators with climate-focused investors, customers, and partners to reach new heights — to date, 2021 and 2022 Foresight 50 ventures have raised over $1.67B and counting. Jeanette Jackson, Foresight CEO says, “Canada possesses the innovation, commercialization, and business talent to lead the world to net zero. If we are going to harness the power of our homegrown climate innovations to their full potential, we need to attract the capital required to support ventures through their scale up and growth journeys. The Foresight 50 is one initiative that helps do just that.”

Foresight 50’s panel of judges, composed of leading cleantech investors, selected 50 ventures based on their investibility, potential economic and job growth impact, leadership team, environmental impact, and probability of success. The 2023 list includes founders and leaders from diverse backgrounds and companies spanning the spectrum of early stage capital raises – from Seed to Series A, B, and beyond.

The Foresight 50 Showcase took place in Calgary this year for the first time. The public celebration on November 8th featured 1-minute pitches from the honouree ventures, and invited investors to meet one-on-one with honourees to explore deal opportunities in an investor matchmaking forum on November 9th.

Foresight 50 is powered by Gowling WLG with support from Alberta Ecotrust FoundationBackStretch Recruitment GroupCopointEaslyNational Angel Capital OrganizationPathways Alliance, and Startup TNT.

Foresight would also like to thank the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP), for providing funding support for its Cleantech Ventures program, part of which makes this initiative possible.

About Foresight Canada:

Foresight is Canada’s cleantech accelerator. Our audacious goal is that Canada be the first G7 country to reach net zero by accelerating cleantech innovation and driving the adoption of climate solutions. Since inception, we’ve supported 1,000+ ventures and collaborated with 2,000+ stakeholders, rightsholders, and partners through domestic and international engagement.

Media Inquiries:
Casey Bohn

GlobeNewswire Distribution ID 8975603

Recursion Announces Data Collaboration Deal with Tempus, Top 50 Supercomputer Ambition Powered by NVIDIA, and Updated Focus of Collaboration with Bayer to Precision Oncology

With additional patient-centric data, compute power, and an exciting new focus for its Bayer collaboration, the company is accelerating the shift of biotech to techbio

SALT LAKE CITY, Nov. 09, 2023 (GLOBE NEWSWIRE) —  Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced two significant updates with their collaborators NVIDIA and Bayer, and a new collaboration with Tempus Labs as it creates infrastructure and expands its ambitions and scope in the precision oncology space.

“Since our founding we have believed that the next generation of biopharma leaders would operate at the intersection of scaled datasets and accelerated computing,” said Chris Gibson, Ph.D., Co-founder and CEO of Recursion. “Today, we are thrilled to share three major initiatives that support this belief and our mission to bring better medicines to patients at speed and scale. With Tempus’s 20 petabytes of fit-for-purpose precision oncology data, NVIDIA’s support in quadrupling our supercomputing power to rapidly and reliably advance the exploration and construction of large AI models, and updating our collaboration with Bayer to rapidly pursue a set of precision oncology programs, we will continue to drive the transformation from BioTech to TechBio together.”

Tempus Collaboration Provides Recursion with Access to Data Containing More Than 20 Petabytes of Proprietary Patient-Centric Oncology Data

Recursion has come to an agreement with Tempus for preferred access to one of the world’s largest proprietary, de-identified, patient-centric oncology datasets, spanning DNA, RNA, health records and more to support the discovery of potential biomarker-enriched therapeutics at scale through the training of causal AI models. By combining the forward genetics approach of Tempus with the reverse genetics approach at Recursion, the company believes it has an opportunity to improve the speed, precision and scale of therapeutic development in oncology. As part of the agreement, Recursion will pay Tempus up to $160M in cash or equity over the next five years in exchange for continued and updated data access and use rights for therapeutic development purposes.

“We share Recursion’s commitment to a data-first approach to precision medicine,” said Eric Lefkofsky, Founder and CEO of Tempus. “We look forward to working in tandem to leverage our multi-modal data to uncover insights that have the potential to advance personalized therapeutics for patients around the world.”

In aggregate, Recursion will now have access to approximately 50 petabytes of proprietary data across biology and chemistry as well as real-world, patient-centric data that is relatable and fit for the purpose of training large-scale AI/ML models, which it plans to use to drive novel therapeutic hypotheses, biomarker strategies, and patient cohort selection.

Top 50 Supercomputer Powered by NVIDIA

To accelerate the impact of the proprietary data Recursion has accumulated, the company has committed to substantially expanding BioHive-1, its on-premise NVIDIA DGX SuperPOD-based supercomputer, adding over 500 NVIDIA H100 Tensor Core GPUs to the more than 300 NVIDIA A100 Tensor Core GPUs already in place to increase its computational capacity 4X. This greatly expanded compute power will support the company’s pipeline, partnerships, and the construction of one of the largest foundation models of its kind across multiple modalities of biology and chemistry.

Based on the June 2023 TOP500 list, Recursion projects that upon completion and benchmarking, BioHive-1 will likely be in the top 50 most powerful supercomputers in the world across any industry and would be the most powerful supercomputer owned and operated by any biopharma company. The company anticipates the enhancement of BioHive-1 to be operational in the first half of 2024.

“A new era in drug discovery is here, and life science and drug discovery companies are leading the way,” said Jensen Huang, founder and CEO of NVIDIA. “Our ongoing collaboration with Recursion will bring scaled biological data together with one of the most powerful supercomputers to decode biology and get to better medicines faster.”

Collaboration with Bayer in Precision Oncology Programs

Recursion announced an updated collaboration with its established partner, Bayer, for a select set of precision oncology programs. This decision allows Bayer to leverage Recursion’s state-of-the-art capabilities to identify novel targets and chemistry applicable to oncology indications. Under the terms of the agreement, the companies may initiate up to seven oncology programs and Recursion is eligible to receive potential, success-based, future payments of up to $1.5 billion plus royalties on net sales.

“Our collaboration with Recursion is a testament to our commitment to shape the future of healthcare, using advancements in AI and drug discovery to push the boundaries of medicine with the aim of providing innovative cancer therapies for patients whose medical needs are not yet met by today’s treatment options,” said Stefan Oelrich, Member of the Board of Bayer AG and President, Pharmaceuticals.

About Recursion
Recursion is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest proprietary biological and chemical datasets. Recursion leverages sophisticated machine-learning algorithms to distill from its dataset a collection of trillions of searchable relationships across biology and chemistry unconstrained by human bias. By commanding massive experimental scale — up to millions of wet lab experiments weekly — and massive computational scale — owning and operating one of the most powerful supercomputers in the world, Recursion is uniting technology, biology and chemistry to advance the future of medicine.

Recursion is headquartered in Salt Lake City, where it is a founding member of BioHive, the Utah life sciences industry collective. Recursion also has offices in Toronto, Montréal and the San Francisco Bay Area. Learn more at www.Recursion.com, or connect on Twitter and LinkedIn.

Forward-Looking Statements
This document contains information that includes or is based upon “forward-looking statements” within the meaning of the Securities Litigation Reform Act of 1995, including, without limitation, those regarding the outcomes and benefits expected from access to the real-world multimodal data held at Tempus; outcomes and benefits of deriving therapeutic hypotheses by linking molecular data and outcomes data; outcomes and benefits of expanding our supercomputer; early and late stage discovery, preclinical, and clinical programs, including timelines for data readouts; licenses and collaborations, including option exercises by partners and additional partnerships; prospective products and their potential future indications and market opportunities; Recursion OS and other technologies; business and financial plans and performance, including cash runway; and all other statements that are not historical facts. Forward-looking statements may or may not include identifying words such as “plan,” “will,” “expect,” “anticipate,” “intend,” “believe,” “potential,” “could,” “continue,” and similar terms. These statements are subject to known or unknown risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements, including but not limited to: challenges inherent in pharmaceutical research and development, including the timing and results of preclinical and clinical programs, where the risk of failure is high and failure can occur at any stage prior to or after regulatory approval due to lack of sufficient efficacy, safety considerations, or other factors; our ability to leverage and enhance our drug discovery platform; our ability to obtain financing for development activities and other corporate purposes; the success of our collaboration activities; our ability to obtain regulatory approval of, and ultimately commercialize, drug candidates; our ability to obtain, maintain, and enforce intellectual property protections; cyberattacks or other disruptions to our technology systems; our ability to attract, motivate, and retain key employees and manage our growth; inflation and other macroeconomic issues; and other risks and uncertainties such as those described under the heading “Risk Factors” in our filings with the U.S. Securities and Exchange Commission, including our most recent Quarterly Report on Form 10-Q and our Annual Report on Form 10-K. All forward-looking statements are based on management’s current estimates, projections, and assumptions, and Recursion undertakes no obligation to correct or update any such statements, whether as a result of new information, future developments, or otherwise, except to the extent required by applicable law.

Media Contact

Investor Contact

GlobeNewswire Distribution ID 8976094